# Pizarra — PT-pseudo_4edb17f79e46 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4edb17f79e46
Task: 1

Encounter: Urology - outpatient on 25 Feb 2025.
Referrer: Dr. S. de Vries (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 9.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.16 ng/mL²
  - PSA velocity: 1.51 ng/mL/yr
  - Prior PSA: 7.5 ng/mL
  - Prostate volume: 57.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7709042 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.16. Prostate volume 57 mL. csPCa 0.77.

Vitals: weight 72 kg, height 177 cm, BMI 23.0, BP 161/76 mmHg, HR 73 bpm. Smoking: Non-smoker.

Chief complaint: A documented upward trajectory in prostate-specific antigen levels alongside a previously negative biopsy necessitates clinical re-assessment.

History: This 54-year-old gentleman works as a retired farmer residing in a ground-floor apartment shared with his partner. He originally entered the diagnostic pathway in May 2023 due to an elevated PSA. A non-smoker with no comorbidities or active medications, he maintains an active routine that includes running five kilometres three times weekly and consumes approximately thirteen units of alcohol each week. Lower urinary tract symptoms remain minimal, reflected by an IPSS score of five, and he explicitly denies haematuria, unexplained weight loss, or bone pain. His surgical past includes a childhood appendectomy and a right knee arthroscopy for a meniscal tear conducted fifteen years prior. Recent visits to an audiology clinic for standard hearing screening noted occasional mild tinnitus, though he otherwise reports feeling well. He commutes roughly sixty minutes by train to reach this facility. A prior biopsy returned negative, and digital rectal examination is normal.

Physical examination: On examination, digital rectal assessment is normal; the prostate reveals a symmetrically enlarged contour, smooth and firm consistency, with no palpable nodules or asymmetry. General inspection shows a blood pressure of 161/76 mmHg with a regular pulse of 73 beats per minute. Peripheral lymphadenopathy and abdominal masses are notably absent.

Patient info: retired farmer; Married; Lives in ground-floor apartment with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 13 units / week; exercise Running 3x/week, 5 km; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Audiology — hearing test.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.82 +/- 0.10   (95% CI 0.62-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.10  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.68 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Does the PSA trend provide evidence that contradicts the prior negative biopsy status?
  - previous_notes (get_previous_notes) -> What was the prior management context, including prior grade and surveillance pathway?

This case hinges on whether the mpMRI findings (radiology_report) or the PSA trajectory (psa_trend) provide sufficient evidence to override the prior negative biopsy, as the guideline criterion points towards biopsy.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA (9.2 ng/mL), PI-RADS 4, prior negative biopsy, PSA velocity (1.51 ng/mL/yr), and csPCa probability (0.7709042). It cannot weigh the qualitative aspects of the mpMRI prose, the specific PSA trajectory details beyond the velocity, or the context of the prior negative biopsy status relative to the PI-RADS 4 score.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests BIOPSY with a high probability (0.82). This suggestion could be wrong because the guideline criterion states *not* to repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed. The prior does not explicitly weigh the conflict between the PI-RADS 4 score and the prior negative biopsy status against the guideline's specific exclusion criteria. The high aleatoric uncertainty (H=0.68) suggests the model struggles with this specific clinical conflict.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology_report (get_mri_report) -> Must determine if the mpMRI shows a PI-RADS 4-5 lesion that warrants re-biopsy, as per the protocol.
psa_trend (get_psa_trend) -> Must determine if the PSA trend provides evidence that contradicts the prior negative biopsy status.
previous_notes (get_previous_notes) -> Must establish the prior management context, including prior grade and surveillance pathway, to assess if the current situation fits the guideline's track record.
laboratory_results (get_laboratory_results) -> Must retrieve the full lab panel to assess PSA density (PSAD) against guideline thresholds.
GUIDELINE ANCHOR
The guideline criterion mandates a re-biopsy when the mpMRI shows a PI-RADS 4-5 lesion, and it explicitly states not to repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Multiparametric MRI Prostate | Date: 10 Feb 2025 | Reporting Unit: Antoni van Leeuwenhoek Imaging Department
The mpMRI report identifies a PI-RADS 4 lesion located in the left peripheral zone, approximately 12 mm. It notes no evidence of extraprostatic extension or seminal vesicle invasion.

get_psa_trend
The PSA trend shows a trajectory from 8.4 ng/mL (May 2023) to 9.2 ng/mL (Feb 2025), indicating a rising trend.

get_previous_notes
The previous notes document a prior biopsy performed in October 2023 which returned negative results. The context indicates a continuing upward trend in PSA levels prompted the current follow-up.

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no information from the retrieved documents raised a specific question about it.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- mpMRI report: PI-RADS 4 lesion located in the left peripheral zone, approximately 12 mm.
- PSA trend: Rising trend from 8.4 ng/mL in May 2023 to 9.2 ng/mL in Feb 2025.

AGAINST Sampling this patient now:
- Previous notes: Prior biopsy was negative.

WHERE THIS LEANS
The mpMRI finding of a PI-RADS 4 lesion aligns with the guideline criterion for re-biopsy, and the rising PSA trend supports the need for re-assessment. This evidence strongly supports proceeding with a biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 4 lesion and rising PSA trend) strongly supports the guideline criterion for re-biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to proceed with biopsy is supported by convergence across all inputs. The guideline criterion mandates re-biopsy for a PI-RADS 4-5 lesion, which was identified in the mpMRI report. This finding was decisive, aligning with the statistical prior and the retrieved evidence. The rising PSA trend further supported the need for re-assessment, confirming the consensus reached by the conference.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
